Gordion BIoscience

Gordion Bioscience is a private, preclinical-stage biotech based in San Diego and Cambridge, operating at the intersection of genomics, machine learning, and oncology. The company's core platform analyzes comprehensive patient tumor genomic data to identify novel, 'invisible' targets and associated predictive biomarkers, aiming to de-risk drug development from the start. Its pipeline includes in-house bispecific antibody programs and an out-licensed program, with a strategic focus on overcoming resistance mechanisms. Backed by academic founders and a scientific advisory board, Gordion is positioned to address significant unmet needs in precision oncology.

A machine learning platform that analyzes real patient tumor whole genome data (exome and dark genome) to identify novel drug targets and their associated predictive biomarkers simultaneously, integrating target identification with patient selection.

Gordion competes in the crowded AI/ML drug discovery space, facing companies like Recursion, Exscientia, and Insilico Medicine, as well as internal efforts at large pharma. Its key differentiator is the focused use of real patient tumor whole genome data to simultaneously find targets and biomarkers, a more integrated approach than many competitors who may focus on one aspect or use different data types.